December 22, 2023 — Quibim, a company pioneering imaging biomarkers for Precision Medicine that has created AI-based software to identify early-stage neurodegenerative diseases, is pleased to announce today the launch of QP-Brain. This follows the product receiving an FDA 510(k) clearance from the US Food and Drug Administration, a CE mark for the European Union and a UKCA mark for the United Kingdom.

December 22, 2023 — Annual low-dose CT screening has been recently shown to result in high cure rates of over 80%, but methods of conducting a lung cancer screening program vary and best practices have yet to emerge.  To address this, the International Association for the Study of Lung Cancer (IASLC) Early Detection and Screening Committee published a perspective that contains considerations for screening program managers to follow.  The stu

December 20, 2023 — Terran Biosciences, Inc., a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received U.S. Food and Drug Administration (FDA) clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.

December 19, 2023 — Prostate cancer patients treated at Advanced Radiation Centers of New York (ARC) became the first in the United States to benefit from the implantation of a novel biodegradable rectal spacer – The BioProtect Balloon Implant System. These pioneering implant procedures were performed by Dr. Shawn H. Zimberg, Medical Director at ARC, a division of Integrated Medical Professionals (IMP).